NEBULA is a deeptech company revolutionizing drug discovery through a proprietary generative AI and physics-based platform that reveals hidden, “undruggable” pockets within any therapeutic target. Unlike traditional AI players that focus on screening known sites, NEBULA operates upstream, unvealing new druggable conformations and accelerating the discovery of transformative therapeutics. Its in silico, data-free approach enables faster, more cost-efficient drug design without heavy experimental infrastructure. With validated proof-of-concept on KRAS-mutant targets, NEBULA aims to become a strategic R&D partner for pharma and biotech companies seeking novel opportunities across oncology and other high-impact therapeutic areas.